Mersana Therapeutics (MRSN)
(Delayed Data from NSDQ)
$3.16 USD
+0.22 (7.48%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $3.15 -0.01 (-0.32%) 5:08 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Income Statements
Fiscal Year end for Mersana Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 37 | 27 | 0 | 1 | 42 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 37 | 27 | 0 | 1 | 42 |
Selling & Adminstrative & Depr. & Amort Expenses | 217 | 230 | 169 | 89 | 72 |
Income After Depreciation & Amortization | -180 | -204 | -169 | -88 | -30 |
Non-Operating Income | 12 | 3 | 0 | 0 | 2 |
Interest Expense | 4 | 3 | 1 | 0 | 0 |
Pretax Income | -172 | -204 | -170 | -88 | -28 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -172 | -204 | -170 | -88 | -28 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -172 | -204 | -170 | -88 | -28 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -183 | -204 | -168 | -87 | -29 |
Depreciation & Amortization (Cash Flow) | -3 | -1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -180 | -204 | -169 | -88 | -30 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 116.11 | 93.65 | 70.58 | 61.49 | 43.49 |
Diluted EPS Before Non-Recurring Items | -1.48 | -2.18 | -2.41 | -1.43 | -0.65 |
Diluted Net EPS (GAAP) | -1.48 | -2.18 | -2.41 | -1.43 | -0.65 |
Fiscal Year end for Mersana Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 10.70 | 7.70 | 10.65 | 7.80 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 10.70 | 7.70 | 10.65 | 7.80 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 32.13 | 51.64 | 67.16 | 65.61 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -21.43 | -43.94 | -56.51 | -57.81 |
Non-Operating Income | NA | 2.93 | 3.30 | 3.22 | 2.62 |
Interest Expense | NA | 1.05 | 1.02 | 1.03 | 0.98 |
Pretax Income | NA | -19.54 | -41.66 | -54.31 | -56.16 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -19.54 | -41.66 | -54.31 | -56.16 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -19.54 | -41.66 | -54.31 | -56.16 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 120.61 | 120.52 | 115.61 | 107.52 |
Diluted EPS Before Non-Recurring Items | NA | -0.16 | -0.35 | -0.47 | -0.52 |
Diluted Net EPS (GAAP) | NA | -0.14 | -0.35 | -0.47 | -0.52 |